Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aurobindo Pharma, an India-based pharmaceutical company, has obtained Health Canada approval for its abbreviated new drug submission for cefotaxime sodium for injection 0.5g, 1g and 2g.
Subscribe to our email newsletter
Cefotaxime sodium for injection is the generic equivalent of Canadian reference product Claforan tablets of Sanofi-Aventis, Canada.
Cefotaxime sodium falls under the anti-infective therapeutic segment and is indicated for the treatment of various infection caused by susceptible organisms, such as pneumonia and lower respiratory infection, urinary tract infection, meningitis, septicemia, cabum abdominis infection, pelvic infection, infection of skin and soft tissues, genital tract infection, infection of bone and joint etc.
Following the approval Aurobindo Pharma now has 13 products approved by Health Canada.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s product portfolio is spread over six major therapeutic/product areas encompassing antibiotics, anti-retrovirals, CVS, CNS, gastroenterologicals, and anti-allergics.